Changes at a Glance: 
Voting Rights Notifications

In the context of a voting rights notification pursuant to Section 33 Para. 1 of the German Securities Trading Act (WpHG), Mr Martin Hesse informed us on 21 January 2021 that he had, among other things, exceeded the reporting threshold of 20%. With reference to this exceeding of the threshold, Mr Hesse, simultaneously acting on behalf of BMSH GmbH, informed us in a letter dated 29 January 2021 with regard to the objectives pursued with the acquisition of the voting rights pursuant to Section 43 Para. 1 Sentence 1 and 3 WpHG:

1. Medios AG has acquired the pharmaceutical wholesaler Cranach Pharma GmbH by way of a share deal from its previous sole shareholder, BMSH GmbH ('transaction' or 'company sale'). The shares in Cranach Pharma GmbH were contributed by BMSH GmbH to Medios AG by way of a contribution in kind. In return for this contribution in kind, Medios AG issued 4,180,000 new Medios AG shares ('capital increase in kind'), so that the share of voting rights held by BMSH GmbH increased accordingly. BMSH GmbH is attributed to Mr Hesse pursuant to Section 34 Para. 1 Sentence 1 No. 1 WpHG.

2. The acquisition of the shares as part of the company sale serves neither to implement strategic objectives nor to generate trading profits.

3. Neither BMSH GmbH nor Mr Hesse intend to acquire further voting rights in Medios AG for their own account or in any other way within the next twelve months.

4. Neither BMSH GmbH nor Mr Hesse intend to exert any influence on the composition of the administrative, management and supervisory bodies of Medios AG.

5. Neither BMSH GmbH nor Mr Hesse seek any material change in the capital structure of Medios AG, including with regard to the ratio of equity and debt financing and the dividend policy.

Furthermore, Mr Hesse has informed us in accordance with Section 43 Para. 1 Sentence 1 and 4 WpHG with regard to the origin of the funds used for the acquisition of the voting rights:

6. The new shares in Medios AG were granted for the contribution of the shares of BMSH GmbH in Cranach Pharma GmbH. To this extent or beyond, financing of the acquisition by equity or borrowed funds was not necessary.

1 February 2021

The Executive Board
Medios AG